Skip to main content
Fig. 1 | International Journal of Retina and Vitreous

Fig. 1

From: Intravitreal aflibercept for the treatment of patients with diabetic macular edema in routine clinical practice in Latin America: the AQUILA study

Fig. 1Fig. 1

Visual acuity outcomes (FAS). a Mean change in BCVA letter score over 12 months in treatment-naïve and previously treated patients; b Mean change in BCVA letter score at Months 6 and 12 in treatment-naïve and previously treated patients by number of injections (< 5 or ≥ 5) received in the first 6 months of treatment; c Mean change in BCVA letter score at Months 6 and 12 in treatment-naïve and previously treated patients by number of injections received overall; d Mean absolute BCVA letter score at Months 6 and 12 in treatment-naïve and previously treated patients; e Proportion of treatment-naïve and previously treated patients by BCVA categorical score change. Missing data imputed using LOCF. Data reported as mean ± SE, where relevant. Data in A were collected monthly ± 15 days; number of patients with assessment at the indicated timepoint indicated below figure. Data in figures B–D, for the 6-month timepoint was collected at 6 months ± 30 days; data for the 12-month timepoint was collected at 12 months ± 60 days. BCVA best-corrected visual acuity, ETDRS Early Treatment Diabetic Retinopathy Study, FAS full analysis set, LOCF last observation carried forward, SE standard error

Back to article page